| Serial Number | 97575104 |
| Word Mark | LION |
| Filing Date | Thursday, September 1, 2022 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Thursday, December 26, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 14, 2025 |
| Goods and Services | Nanoparticle formulations as components of nucleic acid-based vaccines, medicines, and pharmaceutical preparations, namely, nucleic acid drug delivery agents comprising cationic nanoparticle compositions that complex with one or more nucleic acids for the purpose of delivering such nucleic acid to biological cells for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoemulsion compositions as components of nucleic acid-based vaccines, medicines, and pharmaceutical preparations, namely, nucleic acid drug delivery agents in the nature of compounds combining liquid oils, lipids, and surfactants to form nanoparticles to facilitate the delivery of nucleic acids to biological cells, for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Therapeutic preparations in the nature of vaccines as drug delivery agents consisting of nucleic acid, protein or small-molecule compounds for medicines that facilitate the delivery of a wide range of pharmaceuticals delivered via intramuscular injections, intravenous injections, inhalation, transdermal, intradermal, or intranasal methods, for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoparticles and nanoparticle formulations as components of immunotherapeutics, namely, pharmaceutical preparations in the nature of vaccines and nucleic acid, protein or small-molecule medicines for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoparticles and nanoparticle formulations in the nature of active pharmaceutical ingredient drug delivery agents consisting of compositions in the nature of cationic nanoparticles that facilitate the delivery of medical, biological, pharmaceutical, and therapeutic preparations to biological cells for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoparticles and nanoparticle formulations in the nature of compositions for use as drug delivery agents sold as an integral component of pharmaceutical preparations; Nanoparticles and nanoparticle formulations in the nature of active pharmaceutical ingredients for use as drug delivery agents consisting of a biological composition in the form of nanoparticles sold as an integral component of pharmaceutical preparations for intracellular delivery of nucleic acid to biological cells for the treatment and prevention of a wide variety of diseases, namely, cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases, all for pharmaceutical or medical purposes; Pharmaceutical preparations, namely, lipid-enabled drug delivery systems for nucleic acid, protein or small-molecule medicines comprising small interfering RNA, messenger RNA, antisense, microRNA, DNA, cDNA oligotherapeutic, protein therapeutic agents, and small molecules that facilitate the delivery of pharmaceutical preparations to biological cells to enable the targeting of any gene in the human genome to modulate immune response, sold to pharmaceutical companies for use as an integral component for use in the further manufacture of pharmaceutical preparations for the treatment and prevention of a wide variety of diseases, namely, cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Pharmaceutical preparations for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Pharmaceutical preparations, namely, nucleic acid-based delivery agents comprised of nanoparticle carriers and polymers for the delivery of nucleic acid to human cells; Drug carriers for medical use, namely, drug delivery agents consisting of cationic nanoparticles as compositions that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents consisting of emulsions as compositions that facilitate delivery of a wide range of pharmaceuticals |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 9, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | HDT Bio Corp. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Seattle, WA 98501 |
| Event Date | Event Description |
| Friday, September 9, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, September 5, 2022 | NEW APPLICATION ENTERED |
| Saturday, June 17, 2023 | ASSIGNED TO EXAMINER |
| Thursday, July 13, 2023 | NON-FINAL ACTION WRITTEN |
| Thursday, July 13, 2023 | NON-FINAL ACTION E-MAILED |
| Thursday, July 13, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, October 12, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Thursday, October 12, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Saturday, January 13, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, January 13, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, January 15, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, April 26, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Friday, April 26, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Wednesday, February 28, 2024 | FINAL REFUSAL WRITTEN |
| Wednesday, February 28, 2024 | FINAL REFUSAL E-MAILED |
| Wednesday, February 28, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, August 28, 2024 | DIVISIONAL REQUEST RECEIVED |
| Wednesday, August 28, 2024 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Wednesday, August 28, 2024 | TEAS REQUEST TO DIVIDE RECEIVED |
| Wednesday, August 28, 2024 | EXPARTE APPEAL RECEIVED AT TTAB |
| Wednesday, August 28, 2024 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Wednesday, August 28, 2024 | EX PARTE APPEAL-INSTITUTED |
| Tuesday, November 12, 2024 | ASSIGNED TO LIE |
| Tuesday, November 12, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Thursday, November 14, 2024 | DIVISIONAL PROCESSING COMPLETE |
| Friday, December 20, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Friday, December 20, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Friday, December 20, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, December 20, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, December 20, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, December 20, 2024 | EXPARTE APPEAL TERMINATED |